PBM Mergers: Vertical Integration Is Cool – But Don’t Overlook Horizontal Consolidation In Part D
It is hard not to get caught up in the excitement of reinventing health care deliver amid the wave of retail, PBM and insurer merger agreements and rumors. But there is an immediate impact that might be overlooked: the Medicare Part D market is going to be much more consolidated.
You may also be interested in...
Divestiture prevents CVS from gaining even more dominance in the stand-alone Medicare Part D sector with its acquisition of Aetna, assuming the transaction is cleared by the government.
It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.
The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.